0001193125-26-197115
SEC filingArtiva Biotherapeutics remains a pre-revenue clinical-stage biotech with significant operating losses and cash burn, though the company made strategic progress in executive hires and equity restructuring.
Artiva Biotherapeutics continues to operate as a pre-revenue clinical-stage biotechnology company, incurring significant operating losses as it advances its pipeline. Research and development expenses, along with general and administrative costs, remain the primary drivers of net losses. The company has not yet generated any product revenue, and its ability to achieve profitability depends on successful development and commercialization of its candidates.
In December 2025, Artiva executed an option-for-RSU exchange program, converting certain outstanding stock options into restricted stock units for executives. This restructuring is intended to reduce potential dilution while retaining key talent by aligning long-term incentives with shareholder value. The move reflects management's focus on capital efficiency and employee retention.
The company's capital structure consists of common stock and equity-linked instruments. While specific cash runway figures are not disclosed in this narrative, Artiva has historically relied on equity financing and SAFE agreements to fund operations. The recent equity restructuring and leadership additions may position the company for future capital-raising activities, though no specific guidance is provided.
The board comprises eight directors, with Brian Daniels serving as independent Chair. The audit committee includes Elizabeth Hougen (Chair), Brian Daniels, and Laura Stoppel, with Hougen designated as an audit committee financial expert. Artiva has implemented a clawback policy compliant with Dodd-Frank rules and maintains an insider trading policy. Risk oversight is distributed among board committees: the audit committee focuses on financial controls and cybersecurity, the compensation committee on talent and compensation risks, and the nominating committee on governance and ESG initiatives.